multivesicular body subunit 12BGenealiases: C9orf28 · FAM125B
Q-omics provides the consensus-scored MVB12B profile across patient tissues and cancer cell-line models. MVB12B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MVB12B is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, MVB12B RNA expression shows 20,067 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LUAD, and ACC as cancer lineages where MVB12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MVB12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MVB12B survival associations across molecular data types. MVB12B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MVB12B RNA expression–survival associations across cancer types. High MVB12B expression shows unfavorable associations in ACC, but favorable associations in UVM, LUAD, KIRC, PAAD and THCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MVB12B RNA expression.
This table summarizes MVB12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MVB12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MVB12B shows lower tumor expression in LUAD, LUSC, BLCA, UCEC and BRCA and higher tumor expression in LIHC. The LUAD box plot shows higher MVB12B RNA expression in normal versus tumor tissue (log2 FC = −1.792, t-test p < 0.001).
This table shows molecular features associated with MVB12B in patient tissues and cancer cell lines. In patient samples, MVB12B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MVB12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
